BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31155235)

  • 21. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.
    Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y
    J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene aberrations for precision medicine against lung adenocarcinoma.
    Saito M; Shiraishi K; Kunitoh H; Takenoshita S; Yokota J; Kohno T
    Cancer Sci; 2016 Jun; 107(6):713-20. PubMed ID: 27027665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks.
    Seki Y; Mizukami T; Kohno T
    Biomolecules; 2015 Sep; 5(4):2464-76. PubMed ID: 26437441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
    Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
    Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    Fan J; Dai X; Nie X
    J Thorac Oncol; 2018 Mar; 13(3):e45-e48. PubMed ID: 29472061
    [No Abstract]   [Full Text] [Related]  

  • 31. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
    Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
    Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
    Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.